Skip to main content
Premium Trial:

Request an Annual Quote

DNAPrint, Pharsight Enter Pharmacogenomics Partnership

NEW YORK. Aug. 24 – DNAPrint Genomics and scientific developer Pharsight have entered into a collaboration to empower DNAPrint’s pharmacogenomic product development, the company announced on Friday.

The terms of the contract, which is open-ended, call for Mountain View, Calif.-based Pharsight to provide DNAPrint with clinically phenotyped DNA specimens from patients who are taking medications known to elicit variable efficacy.

According to Tony Frudakis, DNAPrint’s CEO, the alliance hopes to reveal drug-reaction traits in patients diagnosed with “general metabolic disorders.”

Further details of the contract were not disclosed.

The collaboration will increase DNAPrint’s specimen database “by about 10 percent” and opens the door for similar deals between the companies, the Sarasota, Fla.-based research firm said in a statement.

Last month, DNAPrint joined forces with a small Malaysian biotech company to tap into government science grants for pharmacogenomic research in that country. 

As GenomeWeb reported, terms of that collaboration called for DNAPrint to join DNAPro to establish DNAPrint Genomics Malaysia. DNAPrint is to own 49 percent of the company, while DNAPro will own 51 percent.  The new company will apply for grants from the Malaysian Ministry of Science and Technology, Frudakis said at the time. 

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.